BLACKSBURG, VIRGINIA, October 17, 2018 – Landos Biopharma, a clinical-stage biopharmaceutical company focused on developing improved oral treatments for autoimmune diseases, is pleased to announce that Dr. Josep Bassaganya-Riera, Chairman and CEO of Landos, will speak on the ‘Applying Artificial Intelligence to Improve Therapy Development Today’ panel at the 2018 BIO Investor Forum, to be held Thursday, October 18 at 3:00PM PT.

The company will also present an update on the company and a review of its novel oral therapeutic clinical program focused on IBD on Wednesday, October 17, 2018, at 9:15AM PT. To view a live webcast of the company presentation, please visit: An archived edition of the presentation will be available through this host for 90 days following the presentation.

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, gut-restricted small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and has completed Phase 1 clinical testing and will initiate Phase 2 studies for Crohn’s disease and ulcerative colitis in 2018. Landos also has a robust pipeline of new compounds for other autoimmune diseases that we will advance to IND in 2019. Landos is headquartered in Blacksburg, VA. For more information,
please visit or contact or follow us @Landosbio.

Company Contacts:

Landos Biopharma:

Josep Bassaganya-Riera


For Media Requests:

Sharon Correia

LaVoie Health Science